Discounted cash flow analysis based risk-adjusted NPV (rNPV) computation is the most prevalent valuation method to value biotech assets. BiopharmaVantage, the specialist life sciences strategy consulting firm describes the dos and don’ts of pharma and biotech asset valuation. The firm recommends, inter alia:

Focus on asset’s top-line potential.
Understand the revenue acceleration.
Understand accruable top-line.
Compute the free cash flow correctly
Be aware of the cash flow in the computation.
Read remaining points (and in more details) here.

About BiopharmaVantage

BiopharmaVantage is a life sciences strategy consultancy that specializes in providing valuation services specifically for the pharma and biotech sector. If you would like to discuss how we can assist you, then please contact us.

Contact:

Katherine Mae

Business Development Manager

BiopharmaVantage, Oxford, UK

Email: [email protected]

Website: www.biopharmavantage.com